Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 15/20 | 0.61 |
| ▸ | ABCC8 | Q09428 | 15/20 | 0.61 |
| ▸ | KCNJ11 | Q14654 | 15/20 | 0.61 |
| ▸ | KCNJ8 | Q15842 | 15/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6432083 | 0.95 | ABCC9 (0.61) | ABCC9ABCC8KCNJ11KCNJ8ALDH1A1 | |
| SCHEMBL6903824 | 0.95 | ABCC9 (0.61) | ABCC9ABCC8KCNJ11KCNJ8ALDH1A1 | |
| SCHEMBL6903919 | 0.95 | ABCC9 (0.61) | ABCC9ABCC8KCNJ11KCNJ8ALDH1A1 | |
| SCHEMBL6434268 | 0.95 | ABCC9 (0.55) | ABCC9ABCC8KCNJ11KCNJ8ALDH1A1 | |
| SCHEMBL6904648 | 0.90 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6910087 | 0.90 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6432162 | 0.88 | ABCC9 (0.52) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL1002731 | 0.86 | ABCC9 (0.73) | ABCC9ABCC8KCNJ11KCNJ8ALDH1A1 | |
| SCHEMBL6908334 | 0.86 | ABCC9 (0.55) | ABCC9ABCC8KCNJ11KCNJ8ALDH1A1 | |
| SCHEMBL6910292 | 0.85 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040097-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2004-04-14 | — | — | EP | claimed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | claimed |
| US-20010036950-A1 | Potassium channel openers | CARROLL WILLIAM A (US) | 2001-11-01 | — | — | US | claimed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | claimed |
| EP-1040097-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2000-10-04 | — | — | EP | claimed |
| WO-1999031059-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 1999-06-24 | — | — | WO | claimed |
| EP-1040097-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| US-20010036950-A1 | Potassium channel openers | CARROLL WILLIAM A (US) | 2001-11-01 | — | — | US | disclosed |
| US-6265417-B1 | MUSCLE RELAXANTS | ABBOTT LABORATORIES | 2001-07-24 | — | — | US | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-1040097-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999031059-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036950-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | ABCC9 300/4885ABCC8 376/4885KCNJ11 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.